^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) + PF-07284892 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Published date:
08/04/2023
Excerpt:
PF-07284892 (initially dose decreased like the prior patient) was continued, and encorafenib + cetuximab were added at their approved doses. After 6 weeks of the combination (study week 12), rapid and complete disappearance of BRAF V600E (and other mutations) in ctDNA occurred together with a −22% decrease in the peritoneal target lesion and resolution of malignant ascites...The patient remained on combination therapy without disease progression for 6 months, three times longer than prestudy encorafenib + cetuximab.
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0361
